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ABSTRACT
Background: Rheumatoid arthritis(RA) is a debilitating condition.Early diagnosis of RA 
can be difficult as the disease may initially be indistinguishable from Undifferentiated 
arthritis(UA). American College of Rheumatology criteria(ACR)is not suitable for 
early diagnosis as its characteristics are fulfilled when bone damage has already taken 
place.Anti-cyclic citrullinated antibodies(Anti-CCP) are highly specific for RA and 
have been used to confirm early diagnosis.
Objective:To determine the prevalence and clinical utility of Anti-CCP antibodies 
in patients with rheumatoid and undifferentiated arthritis at presentation to KNH 
medical clinics.
Design: A cross-sectional descriptive study.
Setting: Kenyatta National Hospital Medical Outpatient Clinics (MOPCs) between 
the month of October 2008 to February 2009.
Results :A total of 95 patients were recruited.The mean age of the patients studied in 
the RA and UA was 44.7 and 41.2(p=0.356) respectively.Sixty four patients(64) satisfied 
ACR criteria.The overall prevalence of Anti-ccp antibodies in the population studied 
was 47.4%.The prevalence of Anti-ccp antibodies in patients who satisfied the ACR 
criteria was 62.5% .The prevalence of Rheumatoid Factor (RF) in patients who satisfied 
the ACR criteria was 50% compared to 9.7% for those who did not(p=0.000).The male 
to female ratio of subjects studied was 1:11
Conclusion:Anti-ccp antibodies are more prevalent in this cohort of patients with 
rheumatoid and undifferentiated arthritis than RF. It was also concluded that ACR 
characteristics correlated well with Anti-ccp and RF. A greater percentage of patients 
who were RF negative were Anti-ccp positive.
INTRODUCTION  
The emphasis in the management of Rheumatoid 
Arthritis is early diagnosis and intervention. The 
hypothesis on which this approach is based is that 
a window of opportunity exists where therapy 
has a disproportionate impact on outcome (1). It 
would appear logical to introduce therapy prior to 
irreversible damage (2).
An inherent problem with earlier assessment is 
accurate disease classification. Pathognomonic 
features of RA such as deformity and nodules are 
related to chronicity and are absent at presentation. 
The American College of Rheumatology (ACR) 
classification criteria for RA (3) include such 
parameters, making them insensitive when applied 
early (4). Also routine laboratory investigations such 
as acute phase markers and X-rays may be normal 
in up to 60 and 70% of patients respectively (5).
Current best practice for early diagnosis of RA is 
reliant on the history and examination findings, with 
supplementary additional investigations. 
 Rheumatoid Factor (RF) has been widely 
used as a screening test for patients with arthritis. 
Although RF is prognostically useful,as it correlates 
with functional (6) and radiographic (7) outcomes 
in both RA and early inflammatory arthritis (8),as a 
diagnostic test it performs poorly, with low sensitivity 
and moderate specificity (9). Used in isolation, RF 
has little diagnostic utility, but has retained its place 
in practice because of its prognostic ability and the 
lack of an alternative test.
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More recently a highly specific autoantibody 
system has been described for RA, in which patients 
develop antibodies to modified(citrullinated) 
arginine residues, and this has resulted in the 
development of the Anti-cyclic citrullinated 
peptide(Anti-ccp) antibody test, which has a 
sensitivity of 68% and a specificity of 97%(10). 
Further development yielded novel peptides 
and a second generation test. The Anti-ccp2 test 
has improved sensitivity (80%comparable to 
Immunoglobulin M-RF(IgM-RF)(70-75%) and 
equivalent specificity(>98%)(11).Moreover,35 
to 40% of RF-negative patients are Anti-ccp 
antibody positive. Anti-ccp antibodies have also 
demonstrated prognostic utility with regard to 
radiographic outcomes (12).
 An ideal strategy for RA diagnosis would 
involve sensitive and specific laboratory markers 
that detect RA early in its course, differentiate 
RA from other rheumatic diseases and provide 
prognostic information regarding an individual’s 
disease progression. Treatment could therefore 
be started early and might help to diminish 
progression to severe erosive arthritis.
 Of patients with RA,65-85% have evidence 
of circulating RF, IgM or Immunoglobulin G(IgG) 
antibodies directed against the Fc portion of IgG(3).
Immunoglobulin A(IgA) and Immunoglobulin 
E(IgE) can sometimes be detected.
 Unfortunately, 3 to 5% of general population 
also have low levels of circulating RF and this 
level increases to 10 to 20% by age 65(13).The 
majority of these patients however will not 
develop RA. As RF can be detected in numerous 
other rheumatologic and inflammatory disorders, 
it is somewhat limited in its usefulness as a sole 
laboratory test for the diagnosis of RA. While RF 
has proven useful in providing some prognostic 
information regarding disease severity, the need 
for an additional and prognostic marker for RA 
is evident (14).
 Anti-ccp antibodies are often found in patients 
with erosive or polyarticular symptoms.Anti-ccp 
antibody formation precedes the development of 
clinical symptoms in some patients with RA and 
multiple studies have now demonstrated that 
the presence of anti-ccp antibodies can provide 
valuable prognostic information regarding the 
aggressiveness of disease progression (15).
 A combined analysis  of  publicat ions 
concerning more than 2000 patients with early 
undifferentiated arthritis found a prevalence of 
23% of Anti-ccp antibodies at baseline. Prevalence 
increased to 51% in more than 1000 patients 
who fulfilled the ACR criteria on follow up for 
18 months. Anti-ccp positive patients had more 
severe radiological destruction during the disease 
course (16).
MATERIALS AND METHODS
Study population: The study was conducted on patients 
attending the medical outpatient clinics at Kenyatta 
National Hospital.
Patient recruitment: Patients 18 years and above 
were consecutively recruited. They were referred 
to medical clinics with arthritis and gave signed 
informed consent. We excluded patients with 
acute febrile illnesses, those who had autoimmune 
disease and those with gouty and septic arthritis. 
All patients who were classified as inflammatory 
arthritis using elevated Erythrocyte Sedimentation 
Rate(ESR) had their ages, sexes and other socio-
demographic characteristics recorded by the principal 
investigator and assistants on an already prepared 
questionnaire.
 Physical examination was carried out and the 
musculosketal system was screened using the Gait, 
Arms, Legs and Spine (GALS) screening system.ACR 
criteria was then applied to classify patients into RA 
and UA. The number of joints swollen and deformed 
were recorded.  Patients were also examined to find 
out whether they had rheumatoid nodules, deformity 
of the upper and lower limb joints. 
Case definition: Arthritis-patient with inflammation 
of the joint, swelling, pain, stiffness and tenderness.
Rheumatoid arthritis-patient with signs and 
symptoms that satisfy the ACR criteria for RA. At 
least four elements of the criteria to be fulfilled.
Undifferentiated arthritis: patient with non specific 
signs and symptoms of arthritis not satisfying the 
classification criteria for RA.
Gout – patient known to have had characteristic 
crystals in the joint fluid and or more than one attack 
of acute arthritis.
Septic arthritis - patient known to have an infection 
(bacterial) in the joint cavity.
Laboratory methods: Consenting patients had about five 
millilitres of venous blood drawn from the forearm 
using a non heparinised needle and syringe and this 
blood was allowed to stand at room temperature to get 
serum for Anti-ccp and RF antibodies. Two millilitres 
of blood was collected in an Ethylene Diamine Tetra 
Acetate(EDTA) bottle for ESR estimation which was 
done immediately. RF was also done immediately. 
Serum for Anti-ccp test was frozen and done as 
a batch at the end of the study period.RF was 
measured by use of agglutination method.Anti-ccp 
antibodies were measured by using Axysm Machine 
that uses automated ELISA for the detection of IgG 
and IgA anti-CCP3 and results were interpreted 
thus:Negative<5.0IU, Positive>5.1IU.ESR was 
measured using the Winthrop method.Elevated ESR 
was interpreted as follows:>15mm/hr and >20mm/h 
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for men and women under 50yr of age respectively 
and >20mm/hr and >30mm/h for men and women 
older  than 50yrs respectively.
Data management and analysis: All data were collected 
on the study proforma and entered into a computer 
database. The data were then cleaned and verified. 
Statistical analysis was done using statistical package 
for social scientists (SPSS) version 15.0 software. 
Data were summarised into means, ranges, ratios 
and then presented in form of pie charts and tables. 
A significant association was deemed present at a 
P-value of <0.05
Ethical considerations: The study was carried out after 
approval from the department of medicine (University 
of Nairobi) and Kenyatta National Hospital ethics 
committee. Patients were included in the study after 
being explained to the purpose of the study and 
giving a signed informed consent. Participation in the 
study was voluntary and patients were at liberty to 
withdraw from the study without any prejudice.  The 
patients right to privacy was respected. Study results 
were given to the primary care physicians to allow 
for provision of better healthcare and confidentiality 
was maintained.
RESULTS
                  
One hundred and thirty one patients with arthritis 
were screened at the Medical Outpatient Clinics. 
One declined informed consent. History and Physical 
Examination  and the screening tool GALS was 
used to screen patients.ESR was carried out on these 
patients and was found elevated in 95 patients and 
these were presumed to have either rheumatoid or 
undifferentiated arthritis. The ACR characteristics were 
applied and 64 patients satisfied the ACR criteria and 
31 had Undifferentiated Arthritis (UA) as they did not 
satisfy the ACR criteria. Both RF and Anti-ccp were 
carried out on these patients. Fourty patients were 
positive for Anti-ccp in the RA group as compared to 
five patients in the UA group.Thirty patients were RF 
positive in the RA group as compared to three patients 
in the UA group.
Socio-demographic characteristics of the patients: The study 
population was 95 patients selected from a group of 
patients referred with arthritis to MOPC. The patients 
age ranged from 18 to 82 years and had a mean age of 
43.5 years. The peak age of the patients studied was 
between 35 to 44 years (Figure 1).
Figure 1
Age distribution for the study group
The sex distribution of the study population was 91.6% female and 8.4% male giving a M:F ratio 
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Rheumatoid arthritis (RA) and Undifferentiated Arthritis 
(UA): Using the ACR criteria, rheumatoid arthritis 
was identified in 67.4% of the patients.There was no 
difference between male and female groups of patients 
in terms of prevalence of RA and UA (P=0.759). In 
addition, mean age was not statistically significant 
between the RA (44.7 years) and UA patients (41.2 
years), P=0.356.The prevalence of Anti-ccp (47.4%) 
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was higher than that of RF (36.8%), P=0.05.62.5% of RA 
patients were Anti-ccp positive compared to 16.1% of 
the UA patients (P=0.000).The titres of Anti-ccp were 
markedly higher for patients who satisfied the ACR 
criteria than those who did not. However there were 
few patients who had higher titres of Anti-ccp who 
were in the UA.Half of RA patients were RF positive.
In UA patients,9.7% were RF positive(p=0.000).
 In the total study population, the total number of 
patients who were RF was 60. Twelve (20%) of these 
patients were Anti-ccp positive 32 of these patients 
who were RF negative satisfied the ACR criteria for 
RA. Of the 32 who satisfied the ACR criteria for RA, 
ten (31%) were Anti-ccp positive. Hence a greater 
percentage of patients would miss treatment for RA 
if RF will solely be relied on. 
 Five patients who were classified as UA using 
ACR criteria had their sera test positive for Anti-
ccp.Three of those patients were RF positive.Three 
of them had negative family history for RA.The 
mean duration of illness was 126 weeks which was 
higher than the mean (61.1weeks) duration for the 
total study population.The mean Anti-ccp titre was 
127.64iu compared to the mean for the whole study 
population that was 59.68iu.The mean joint count 
was 10.4,similar to the mean found for patients who 
were classified as RA.The mean age of this group of 
patients was 45.4 years and hence comparable with 
the mean for the study population.
 Family history of RA was present in 25.3% of all 
patients. Family history of RA was reported among 
25 and 25.8% of the RA and UA patients respectively 
hence was not significantly associated to presence or 
absence of RA (P=0.932).
 The range of duration of illness was 2-260 weeks 
with a mean duration of illness of 62.8 weeks ± 54.8SD. 
The mean duration of illness was higher by about ten 
weeks among the RA patients than the UA patients. 
However, the difference between the two means was 
not significant (P=0.4).                   
 The  range of joints was 2-20 joints with a mean 
number of joints involved among the 95 patients 
studied being 9.6±3.2SD. The number of joints was 
significantly different between the RA and the UA 
patients (P=0.011). The average number of joints 
involved among the RA patients was higher (10.2 
joints) than the UA patients (8.4 joints).
                                                                                
DISCUSSION
From the results, it can be seen that the majority of 
the study population were female (91.6%)(M:F=1:10).
This female preponderance is keeping with other 
studies done previously (17).The mean age of patients 
classified as RA as per the ACR criteria was 44.7 years 
as compared with that of UA which was 41.2 years 
but this was not statistically significant between the 
two groups. This figure is closely similar to one found 
by Oyoo (17) who found this age to be 44.5years.
From our study we can deduce that inflammatory 
arthritis afflicts the relatively young and productive 
members of  our society hence the need to control this 
condition early enough so as to prevent morbidity 
and mortality.
 Sixty four patients (67.4%) satisfied the ACR 
criteria and were thus classified as RA.These results 
are similar with those found at baseline in an early 
arthritis clinic by Harrison, B. J., et al (18). Among 323 
patients studied,67% satisfied the ACR criteria for 
RA.Higher number of patients may have satisfied the 
ACR criteria due to recall bias of the study subjects.
This is because questions regarding the ACR criteria 
may be misinterpreted by the patient and hence 
explain the high number of patients who satisfied the 
ACR criteria.Furthermore the sensitivity and speficity 
of ACR is quite low for the diagnosis of early RA.
 The overall prevalence of Anti-ccp was 47.4% 
compared to 36.8% for RF. Thus the population with 
inflammatory arthritis who were Anti-ccp positive 
was significantly higher than that of RF (p=0.05) and 
hence the confirmation from this study that Anti-
ccp is usually picked early in the disease process 
as compared to RF which is usually picked late in 
the disease process.Vittecoq and coworkers (38) in a 
similar study found the prevalence of Anti-ccp to be 
41% and that of RF to be 28% at presentation to the 
clinician and these results are comparable to those 
of our study.They concluded that Anti-ccp detected 
more positive subjects compared to RF.
 The greater majority of the patients classified as 
RA as per the ACR criteria had their blood test positive 
for Anti-ccp(62.5%) as compared to UA(16.1%) which 
was statistically significant (p=0.000).Forty(88.9%) of 
the patients who tested positive for Anti-ccp were 
classified as RA Lee D.M et al (19) found almost a 
similar figure of 83% in these subset of patients.Hence 
Anti-ccp is significantly correlated with the ACR 
criteria in classifying patients into RA and UA.
 RF was positive in 50% of the patients classified 
as RA as compared to 9.7% classified as UA(p=0.000).
The prevalence of RF in this cohort of patients 
classified as RA is lower than earlier studies (21)
that had a prevalence of 70 to 80%. This prevalence 
might have been lower given the fact that most of 
the patients recruited into our study had a shorter 
duration of disease (62.8 weeks) than earlier studies 
(64.97 months).This may also have been due to the 
fact that the researchers in these studies may not have 
excluded patients who had co-mobidities that can 
cause RF to be positive. Such patients were excluded 
from our study. Furthermore,RF tends to become 
positive as the disease progresses.
 The joints involved in the two groups were 
statistically significant (10.2 in RA as compared to 8.4 
in UA p=0.011). Since the majority of the patients who 
had RA as per the ACR criteria had positive Anti-ccp, 
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we can deduce that joint count positively correlated 
with Anti-ccp which as we know is associated with 
more erosive and severe forms of RA. Anti-ccp 
has been shown to be an independent predictor of 
radiological damage and progression (20).
 In the total study population,60 patients were 
RF negative,20% of whom had positive Anti-ccp .This 
produces similar results obtained in other studies that 
found a prevalence of 20-43%(22). Lee D. M. et al (19) 
found 34% of patients who were RF negative testing 
positive for Anti-ccp.These values suggest important 
diagnostic utility where previously serology had been 
unhelpful. Hence from this prevalence of Anti-ccp in 
seronegative individuals, using Anti-ccp antibody 
would appear to select seronegative RA patients 
and so may have important implications for patient 
management.Of these patients who were RF negative, 
32 satisfied the ACR criteria for RA. This again shows 
that RF was highly seronegative in patients who 
satisfied the ACR criteria.This in clinical practice 
may cause diagnostic and management difficulties.
Of the 32 who satisfied the ACR criteria and were RF 
negative, ten were Anti-ccp positive.This also strongly 
suggests that a greater number of patients with early 
arthritis will test positive for Anti-ccp earlier than 
they do for RF.
 Five patients classified as UA tested positive for 
Anti-ccp which was 5.26% of the total population 
studied.These group of patients had higher titres 
for Anti-ccp than the average for the whole study 
population hence a conclusion can be drawn that 
despite being negative for ACR,these patients can 
still be presumed to have RA.Furthermore,three out 
of five of these patients had their sera test positive for 
RF.Their mean joint count and the age never differed 
significantly from the total population.
 Their mean Anti-ccp titres (127.64iu) were away 
above the average for the whole study group (59.8iu).
This information is important as it tells us that Anti-
ccp can be used to diagnose patients who have RA 
despite the fact that they have not satisfied the ACR 
criteria for RA. 
 These five patients diagnosis of RA may have 
been missed because of their non-specific signs and 
symptoms.These are the patients who benefit most 
from Anti-ccp when the diagnosis of RA is in doubt 
and hence its clinical utility.
 It can therefore be concluded that there is a high 
prevalence of Anti-ccp in patients with inflammatory 
arthritis and that the prevalence was higher in those 
who satisfied ACR  criteria.The prevalence of RF in 
this same group of patients was lower than that of 
Anti-ccp.The prevalence of RF was also lower than 
that of Anti-ccp in those who satisfied the ACR 
criteria.
 A high percentage of patients with inflammatory 
arthritis satisfied the ACR criteria at 67.4%. Anti-ccp 
was  found to be  more sensitive than RF. Many patients 
(20%) who were RF negative were Anti-ccp positive.
Anti-ccp should be done in a patient presenting with 
inflammatory arthritis where the diagnosis of RA 
may be in doubt.
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